Health-related Quality of Life Consequences of Implantable Cardioverter Defibrillators

Results from MADIT II

Published in: Medical Care, v. 45, no. 5, May 2007, p. 377-385

Posted on RAND.org on January 01, 2007

by Katia Noyes, Ethan Corona, Jack Zwanziger, W. Jackson Hall, Hongwei Zhao, Hongkun Wang, Arthur J. Moss, Andrew W. Dick

Read More

Access further information on this document at www.lww-medicalcare.com

This article was published outside of RAND. The full text of the article can be found at the link above.

BACKGROUND: Implantable cardioverter defibrillators (ICDs) improve survival and extend lives of patients with severe heart disease. OBJECTIVE: The authors sought to evaluate the impact of ICDs on health-related quality of life (HRQOL) during the first 3 years after implantation. Subjects: A total of 1089 patients from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) were randomized to an ICD or medical treatment only. MEASURES: Health Utility Index (HUI3) at baseline, 3, 12, 24, and 36 months following randomization; survival data. RESEARCH DESIGN: The authors constructed mean profiles of HRQOL for living patients, estimated overall quality-adjusted life years (QALYs), separately by treatment arm, and calculated cumulative QALY gains/losses as the difference between the areas under the treatment specific HRQOL profiles. Multivariate fixed effect regression models were developed to impute the missing HRQOL data using baseline patient characteristics (age, gender, treatment, HUI3 score, diabetes, diuretics use, and NYHA class). Bootstrapped standard errors were calculated for the estimated differences in HRQOL gains/losses between treatment arms. Similarly, the authors performed subgroup analyses (by gender, age, and baseline NYHA class, blood urine nitrogen, ejection fraction, and QRS). RESULTS: There were no differences in QALYs loss for living patients by treatment group (-0.037, P = 0.64) or in overall QALYs loss by treatment group (0.043, P = 0.37) over 3 years. In subgroup analysis, female subjects demonstrated a trend towards greater survival benefit (0.298, P = 0.07) and overall QALYs (0.261, P = 0.14). CONCLUSIONS: Adverse effects of the ICD on HRQOL together with lower HRQOL among survivors may offset the 3-year survival benefits of ICDs.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.